SC 13G/A | 2024-02-14 | Avidity Partners Management LP | Karyopharm Therapeutics Inc. | 11,188,743 | 9.5% | EDGAR |
SC 13G/A | 2024-02-14 | Palo Alto Investors LP | Karyopharm Therapeutics Inc. | 5,102,193 | 4.4% | EDGAR |
SC 13G | 2024-02-13 | VANGUARD GROUP INC | Karyopharm Therapeutics Inc. | 8,710,158 | 7.6% | EDGAR |
SC 13G/A | 2024-02-12 | Rubric Capital Management LP | Karyopharm Therapeutics Inc. | 0 | 0.0% | EDGAR |
SC 13G/A | 2024-01-25 | BlackRock Inc. | Karyopharm Therapeutics Inc. | 10,071,677 | 8.8% | EDGAR |
SC 13G/A | 2024-01-22 | STATE STREET CORP | Karyopharm Therapeutics Inc. | - | 1.8% | EDGAR |
SC 13G/A | 2023-07-10 | STATE STREET CORP | Karyopharm Therapeutics Inc. | - | 1.9% | EDGAR |
SC 13G/A | 2023-02-14 | Avidity Partners Management LP | Karyopharm Therapeutics Inc. | 11,381,073 | 9.9% | EDGAR |
SC 13G/A | 2023-02-14 | Chione Ltd | Karyopharm Therapeutics Inc. | 4,400,000 | 3.9% | EDGAR |
SC 13G/A | 2023-02-14 | Palo Alto Investors LP | Karyopharm Therapeutics Inc. | 5,655,676 | 5.0% | EDGAR |
SC 13G/A | 2023-02-14 | COMMODORE CAPITAL LP | Karyopharm Therapeutics Inc. | 1,935,609 | 1.7% | EDGAR |
SC 13G | 2023-02-10 | Rubric Capital Management LP | Karyopharm Therapeutics Inc. | 8,294,621 | 7.3% | EDGAR |
SC 13G/A | 2023-02-02 | STATE STREET CORP | Karyopharm Therapeutics Inc. | - | 7.3% | EDGAR |
SC 13G/A | 2023-01-26 | BlackRock Inc. | Karyopharm Therapeutics Inc. | 8,508,237 | 10.5% | EDGAR |
SC 13G | 2023-01-20 | BlackRock Inc. | Karyopharm Therapeutics Inc. | 8,508,237 | 10.5% | EDGAR |
SC 13G | 2022-12-08 | Avidity Partners Management LP | Karyopharm Therapeutics Inc. | 11,351,819 | 9.9% | EDGAR |
SC 13G | 2022-05-09 | COMMODORE CAPITAL LP | Karyopharm Therapeutics Inc. | 4,011,052 | 5.1% | EDGAR |
SC 13G/A | 2022-02-14 | Palo Alto Investors LP | Karyopharm Therapeutics Inc. | 5,470,452 | 7.2% | EDGAR |
SC 13G/A | 2022-02-11 | STATE STREET CORP | Karyopharm Therapeutics Inc. | - | 7.3% | EDGAR |
SC 13G/A | 2022-02-11 | Kauffman Michael | Karyopharm Therapeutics Inc. | 4,078,317 | 5.2% | EDGAR |